Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Longeveron ( (LGVN) ) has issued an announcement.
On August 8, 2025, Longeveron announced the pricing of a public offering of its Class A common stock, which closed on August 11, 2025. The offering, managed by H.C. Wainwright & Co., is expected to generate approximately $5 million upfront, with an additional potential $12.5 million from short-term warrants. The proceeds will support the development of laromestrocel for various conditions and regulatory activities.
The most recent analyst rating on (LGVN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.
Spark’s Take on LGVN Stock
According to Spark, TipRanks’ AI Analyst, LGVN is a Neutral.
Longeveron’s overall stock score is primarily impacted by its financial performance and technical analysis, both of which highlight significant challenges. The company’s operational losses and bearish technical indicators weigh heavily on the score. However, the recent FDA approval for a pivotal clinical trial provides a positive outlook, offering potential future growth opportunities.
To see Spark’s full report on LGVN stock, click here.
More about Longeveron
Longeveron is a clinical stage biotechnology company focused on developing regenerative medicines for life-threatening, rare pediatric, and chronic aging-related conditions. Their lead product, laromestrocel (Lomecel-B™), is an allogeneic mesenchymal stem cell therapy with potential applications across various diseases, including hypoplastic left heart syndrome, Alzheimer’s disease, and pediatric dilated cardiomyopathy.
Average Trading Volume: 504,077
Technical Sentiment Signal: Sell
Current Market Cap: $10.29M
See more data about LGVN stock on TipRanks’ Stock Analysis page.